M Skorvanek1, Z Gdovinova, J Rosenberger, R Ghorbani Saeedian, I Nagyova, J W Groothoff, J P van Dijk. 1. Department of Neurology, Safarik University, Kosice, Slovak Republic; Department of Neurology, L. Pasteur University Hospital, Kosice, Slovak Republic; Graduate School Kosice Institute for Society and Health, Safarik University, Kosice, Slovak Republic.
Abstract
OBJECTIVES: Fatigue and apathy are two of the most common and most disabling non-motor symptoms of Parkinson's disease (PD). They have a high coincidence and can often be confused; moreover, their relationship is not fully understood. The aim of our study was to describe the coincidence of apathy with different fatigue domains in the presence/absence of depression and to separately describe the associations of different aspects of primary and secondary fatigue with apathy and other clinical and disease-related factors. MATERIALS AND METHODS: A total of 151 non-demented patients with PD were examined using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Starkstein Apathy Scale, Multidimensional Fatigue Inventory (MFI), Beck Depression Inventory-II, and Epworth Sleepiness Scale. RESULTS: The prevalence and severity of fatigue and apathy were significantly higher in depressed PD patients. However, our results show that depression, fatigue, and apathy can be clearly distinguished in PD. Apathy was associated with the MFI's-reduced motivation domain in both depressed and non-depressed patients. However, apathy was associated with mental fatigue aspects only in non-depressed patients, and it was not related to the physical aspects of fatigue in any of the studied groups. CONCLUSIONS: Although the pathophysiology of fatigue and apathy in PD is clearly multifactorial, in a proportion of PD patients, these symptoms are associated with depression, dopaminergic depletion in the mesocorticolimbic structures, and disruption of the prefrontal cortex-basal ganglia axis. Therefore, in some PD patients, adequate management of depression and optimal dopaminergic medication may improve both fatigue and apathy.
OBJECTIVES:Fatigue and apathy are two of the most common and most disabling non-motor symptoms of Parkinson's disease (PD). They have a high coincidence and can often be confused; moreover, their relationship is not fully understood. The aim of our study was to describe the coincidence of apathy with different fatigue domains in the presence/absence of depression and to separately describe the associations of different aspects of primary and secondary fatigue with apathy and other clinical and disease-related factors. MATERIALS AND METHODS: A total of 151 non-demented patients with PD were examined using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Starkstein Apathy Scale, Multidimensional Fatigue Inventory (MFI), Beck Depression Inventory-II, and Epworth Sleepiness Scale. RESULTS: The prevalence and severity of fatigue and apathy were significantly higher in depressed PDpatients. However, our results show that depression, fatigue, and apathy can be clearly distinguished in PD. Apathy was associated with the MFI's-reduced motivation domain in both depressed and non-depressedpatients. However, apathy was associated with mental fatigue aspects only in non-depressedpatients, and it was not related to the physical aspects of fatigue in any of the studied groups. CONCLUSIONS: Although the pathophysiology of fatigue and apathy in PD is clearly multifactorial, in a proportion of PDpatients, these symptoms are associated with depression, dopaminergic depletion in the mesocorticolimbic structures, and disruption of the prefrontal cortex-basal ganglia axis. Therefore, in some PDpatients, adequate management of depression and optimal dopaminergic medication may improve both fatigue and apathy.
Authors: Benzi M Kluger; Karen Herlofson; Kelvin L Chou; Jau-Shin Lou; Christopher G Goetz; Anthony E Lang; Daniel Weintraub; Joseph Friedman Journal: Mov Disord Date: 2016-02-16 Impact factor: 10.338
Authors: Christoph Mueller; Anto P Rajkumar; Yi Min Wan; Latha Velayudhan; Dominic Ffytche; Kallol Ray Chaudhuri; Dag Aarsland Journal: CNS Drugs Date: 2018-07 Impact factor: 5.749
Authors: Aylin Mehren; Jale Özyurt; Paula Zu Klampen; Svenja Boekhoff; Christiane M Thiel; Hermann L Müller Journal: J Neurooncol Date: 2018-07-03 Impact factor: 4.130
Authors: Karen I Connor; Eric M Cheng; Frances Barry; Hilary C Siebens; Martin L Lee; David A Ganz; Brian S Mittman; Megan K Connor; Lisa K Edwards; Michael G McGowan; Barbara G Vickrey Journal: Neurology Date: 2019-03-22 Impact factor: 9.910
Authors: Graham M L Eglit; Francesca Lopez; Dawn M Schiehser; Eva Pirogovsky-Turk; Irene Litvan; Stephanie Lessig; J Vincent Filoteo Journal: Mov Disord Clin Pract Date: 2020-12-10
Authors: Emmanuelle Schmitt; Paul Krack; Anna Castrioto; Helene Klinger; Amelie Bichon; Eugénie Lhommée; Pierre Pelissier; Valerie Fraix; Stephane Thobois; Elena Moro; Pablo Martinez-Martin Journal: Mov Disord Clin Pract Date: 2018-03-23